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   Estrogen receptor a (ERa) is a ligand-inducible transcription factor that mediates the
biological effects of estrogens and antiestrogens. Many point mutations in the human ERa
gene have been reported to be associated with breast cancer, endometrial cancer, and
psychiatric diseases. However, functional analyses for most mutants with amino acid changes
are still lacking. In the present study, to investigate the effects of point mutations on the
function, gel-shift assays and luciferase assays were performed for eight kinds of mutated
ERa proteins, including a single nucleotide change of C207G (N69K), G478T (G160C),
T887C (L296P), A908G (K303R), C926T (S309F), A1058T (E353V), A1186G (M396V) and
G1231deletion (411fsX7). The mutated ER xpression plasmids were constructed by site-
directed mutagenesis. With gel-shift assays using in vitro translated ERa proteins, binding to
the consensus estrogen response element (ERE) was observed for the mutated ERa proteins
except ERa (G160C) and ERa (411fsX7), the binding of which was comparable with that of
the wild type. Western blot analyses howed that ERa (G160C) could not be efficiently
translated with the in vitro transcription/translation system and that ERa (411fsX7) produced
a truncated protein. To investigate the transactivation potency, wild-type or mutated ERa
expression plasmids were cotransfected with pGL3-3EREc38 reporter plasmid into human
breast adenocarcinoma MDA-MB-435 cells. The concentration-response curves (10 pM - 100
nM E2) of the mutant ERa proteins except ERa (E353V) and ERa (411fsX7) were similar to
that of wild-type ERa. However, at a low level of E2 (100 pM), the mutants ERa (N69K),
ERa (L296P), ERa (S309F), and ERa (M396V) showed a significant decrease of
transactivation compared with that of the wild-type ERa. The mutants ERa (E353V) and
ERa (411fsX7) did not show responsiveness to E2 and antiestrogens, 4-hydroxytamoxifen
(4OHT) and ICI 182,780. The mutant ER (S309F) showed decreased responsiveness for the
antiestrogenicity of 4OHT. In conclusion, we found that some of the naturally occurring
human ERa mutants with amino acid changes may have an altered responsiveness to estrogen
and antiestrogens.
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31. Introduction
   Estrogens play a crucial role in female sexual development and in the regulation of the
menstrual cycle, have important effects on prostatic hyperplasia, protective effects on the
cardiovascular system, and influence lipid and bone metabolism [1]. In addition, estrogens are
involved in the growth and development of both uterine and mammary cancers [2,3]. The
effects of estrogens are mediated primarily via specific nuclear receptors, estrogen receptors
(ERs), which function as ligand-inducible transcription factors [4]. ER is expressed in two
thirds of breast cancers and endometrial cancers, and is used as a guide for hormonal therapy
and for the prognosis [5,6].
   Two ER subtypes, ERa  and ERb , encoded by different genes, have been isolated in
mammals [7,8]. Most of the biological actions exerted by estrogens are mediated by ERa [9].
Upon binding estrogens, the receptor dimerizes and binds to the estrogen response element
(ERE) located in the 5’-flanking region of estrogen-responsive genes. The ligand-activated
ERa  interacts with transcription factors and other components of the transcription complex to
modulate gene expression [10]. ERa , like other members of the nuclear receptor superfamily,
contains six functional domains designated A to F [11]. The amino-terminal A/B region of the
receptor exhibits a hormone-independent transactivation function (Fig. 1). The C region is
principally involved in receptor-DNA interaction. The D region contains a part of the ligand-
dependent, transactivation domain AF-2a and a portion of the nuclear localization signal. The
carboxyl-terminal domains (E/F) are structurally and functionally complex and contain
hormone binding, dimerization, and hormone-dependent transactivation functions [12,13].
  A number of point mutations of ERa  have been identified in patients with a variety of
disease states, including breast cancer, endometrial cancer, and psychiatric diseases [14].
Conclusive studies to determine whether they are somatic mutations or genetic
polymorphisms have been limited. Furthermore, their correlations with the clinical features
have not been completely determined. It should be noted that some of these are silent
mutations or polymorphisms that do not affect the protein sequence, despite their association
4with disease states. Regarding mutations that cause amino acid changes, a few studies have
sought to characterize the ERa  mutants [14]. In these studies, the assessed mutations and the
experimental methods used were different. Furthermore, functional analyses for most of the
ERa  mutants still remain to be performed. To address these issues, we sought to examine the
effects of the mutations on the function of ERa  with a unified method for multiple mutants.
The present study focused on eight mutations existing in various domains, including C207G
(N69K) [15], G478T (G160C) [16-18], T887C (L296P) [19], A908G (K303R) [18,20],
C926T (S309F) [17,18,21], A1058T (E353V) [22], A1186G (M396V) [15] and
G1231deletion (411fsX7; frame-shift at codon 411 resulting in the termination at codon 418)
[23]. Gel-shift assays and luciferase assays were performed to investigate the binding affinity
to DNA, the transcriptional activity and the responsiveness to agonists or antagonists of these
ERa  mutants.
2. Materials and Methods
2. 1. Chemicals and reagents
   Taq DNA polymerase was obtained from Greiner Japan (Tokyo, Japan). Restriction
enzymes were purchased from Takara (Kyoto, Japan), Nippon Gene (Tokyo, Japan), or New
England Biolabs (Beverly, MA). Primers were commercially synthesized at Hokkaido System
Sciences (Sapporo, Japan). 17b -Estradiol (E2) and 4-hydroxytamoxifen (4OHT) were
obtained from Sigma-Aldrich (St. Louis, MO). 7a -[9 (4,4,5,5,5-
Pentafluoropentylsulfonyl)nonyl] estra-1,3,5(10)-triene-3,17b -diol (ICI 182,780) was
purchased from Tocris Cookson (Bullsin, MO). phRL-TK plasmid and a dual-luciferase
reporter assay system were from Promega (Madison, WI). Lipofectamine transfection reagent
was from Invitrogen (Melbourne, Australia). A pGL3 plasmid containing three copies of
EREc38 (pGL3-3EREc38) was a generous gift from Dr. Carolyn M. Klinge (University of
Louisville School of Medicine, Louisville, KY). The wild-type human ERa  expression vector
(pSG5-HE0), constructed previously [24,25], was a gift from Dr. Pierre Chambon (Institut de
5genetique et de Biologie Moleculaire et Cellulaire, Strasbourg, France). [g -32P]ATP was from
Amersham (Buckinghamshire, United Kingdom). Mouse anti-human ERa  monoclonal
antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). All of the other chemicals
and solvents were of the highest grade commercially available.
2.2. Construction of expression plasmids of mutated ER by site-directed mutagenesis
   To construct the expression vectors of mutated ERa ,  single nucleotide change was
inserted into the wild-type ERa  expression vector by site-directed mutagenesis with a
QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA). The forward and reverse
mutagenic primers were as follows:
C207G-S: 5’-CCG CCG CCA AGG CGC AGG TCT ACG GTC AGA C-3’
C207G-AS: 5’-GTC TGA CCG TAG ACC TGC GCC TTG GCG GCG G-3’
G478T-S: 5’-GAT AAT CGA CGC CAG TGT GGC AGA GAA AGA TTG GCC-3’
G478T-AS: 5’-GGC CAA TCT TTC TCT GCC AC TG GCG TCG ATT ATC-3’
T887C-S: 5’-CTT TGG CCA AGC CCG CC  ATG ATC AAA CGC TCT AAG-3’
T887C-AS: 5’-CTT AGA GCG TTT GAT CAT GG  CGG GCT TGG CCA AAG-3’
A908G-S: 5’-CAA ACG CTC TAA GAG GAA CAG CCT GGC CTT GTC CC-3’
A908G-AS: 5’-GGG ACA AGG CCA GGC TGT TCC TCT TAG AGC GTT TG-3’
C926T-S: 5’-GAA CAG CCT GGC CTT GTT CCT GAC GGC CG-3’
C926T-AS: 5’-CGG CCG TCA GGA ACA AGG TTA GGC TGT TC-3’
A1058T-S: 5’-CAA CCT GGC AGA CAG GGT CT GGT TCA CAT G-3’
A1058T-AS: 5’-CAT GTG AAC CAG CA  CCT GTC TGC CAG GTT G-3’
A1186G-S: 5’-GTC TGG CGC TCC GTG GAG CAC CCA GTG AAG CTA C-3’
A1186G-AS: 5’-GTA GCT TCA CTG GGT GCT CCA GG AGC GCC AGA C-3’
G1231del-S: 5’-GCT CCT AAC TTG CTC TTG ACA GGA ACC AGG G-3’
G1231del-AS: 5’-CCC TGG TTC CTG CA AGA GCA AGT TAG GAG C-3’
Mutated sites are indicated by underlined bold letters. Nucleotide sequences were confirmed
by DNA sequencing analyses.
62.3. Gel shift assay
   The oligonucleotide for the consensus ERE (5’-GTC CAA AGT CAG GTC ACA GTG
ACC TGA TCA AAG TT-3’) was from the Xenopus vitellogenin A2 gene [26]. The
oligonucleotide was labeled with [g -32P] ATP using T4 polynucleotide kinase (Toyobo). The
wild-type and mutated ERa  proteins were synthesized using TNT quick coupled
transcription/translation systems (Promega). The reaction mixture contained 5 m L of the in
vitro translated ERa  protein, 2 µg of poly(dI-dC), 1 µg of salmon sperm DNA, and 30 fmol of
the radiolabeled probe (~50,000 cpm) in a final volume of 15 µL of binding buffer [25 mM
HEPES-KOH (pH 7.9), 0.5 mM EDTA, 50 mM KCl, 10% glycerol, 0.5 mM DTT, and 0.5
mM (p-amidinophenyl) methanesulfonyl fluoride]. Binding reactions were performed on ice
for 30 min. To determine the specificity of the binding to the oligonucleotides, competition
experiments were conducted by coincubation with 50- and 200-fold excesses of unlabeled
competitors. In super-shift assays, 2 µg of anti-ERa  monoclonal antibodies were preincubated
with the in vitro translated ERa  protein on ice for 20 min. The DNA-protein complexes were
separated under nondenaturing conditions on 4% polyacrylamide gels with 0.5 X Tris-borate
EDTA as the running buffer. The gels were dried, and then the DNA-protein complexes were
detected and quantified with a Fuji Bio-Imaging Analyzer BAS 1000 (Fuji Film, Tokyo,
Japan).
2.4. SDS-PAGE and Western blot analyses of in vitro translated wild-type or mutated ER
proteins
   SDS-polyacrylamide gel electrophoresis and Western blot analysis for the in vitro
translated ERa  proteins were performed according to Laemmli [27]. The in vitro
transcription/translation mixtures including the wild-type or mutated ERa  expression
plasmids (4 µl) were separated on 15% polyacrylamide gel and transferred electrophoretically
to a nitrocellulose membrane. A mixture including an empty pSG5 vector was applied as a
negative control. Mouse anti-human ERa  tibody was used. Biotinylated anti-mouse IgG
7and a VECTASTAIN ABC kit (Vector Laboratories, Burlingame, CA) were used for
diaminobenzidine staining.
2.5. Cell culture, transfection, and luciferase assay
   The human breast adenocarcinoma cell line MDA-MB-435, which is ER-negative, was
obtained from American Type Culture Collection (Rockville, MD). The cells were cultured in
DMEM (Nissui Pharmaceutical, Ibaraki, Japan) supplemented with 10% (v/v) fetal bovine
serum (Invitrogen). These cells were maintained at 37°C under an atmosphere of 5% CO2-
95% air. A transient expression system using the luciferase reporter gene was used to
characterize the function of the mutated ERa  proteins. The cells (2 X 105) were seeded into
24-well plates and then incubated for 24 hr. The medium was replaced with a phenol red-free
DMEM medium (Invitrogen) containing 10% dextran-coated charcoal-treated fetal bovine
serum. After 24 hr, the cells were cotransfected with 450 ng of pGL3-3EREc38 plasmid, 50
ng of control reporter plasmid (phRL-TK), and 500 ng of each ERa  expression plasmid using
Lipofectamine transfection reagent. After 24 h of transfection, the medium was replaced with
medium containing 0.1% (v/v) DMSO or various concentrations (10 pM - 100 nM) of E2. For
the inhibition studies, the transfected cells were incubated with 100 nM of 4OHT or ICI
182,780 in the absence or presence of 10 nM of E2. After 24 h of treatment with the agonist
or antagonist, the cells were resuspended in passive lysis buffer, and then the luciferase
activity was measured with a luminometer (ARVO MX, PerkinElmer, Osaka, Japan) using the
dual-luciferase reporter assay system. The relative luciferase activities were normalized with
the Renilla luciferase activities. To confirm the reproducibility of the luciferase assays, three
independent experiments were performed for each assay.
2.6. Statistical analyses
   Data are expressed as mean ± SD of triplicate determinations. Statistical significance was
determined by analysis of variance (ANOVA) followed by Dunnett’s test for multiple
comparisons. A value of P < 0.05 was considered statistically significant.
83. Results
3.1. Binding of mutated ER proteins to consensus ERE
   To examine the binding potency of the mutated ERa  proteins to the consensus ERE, gel
shift assays were performed. In vitro translated wild-type or mutated ERa  proteins were
incubated with a 32P-labeled consensus ERE. Wild-type ERa  showed a clear shifted band,
which was super-shifted with the anti-ERa  antibody (Fig. 2A). No super-shifted band was
observed with normal mouse IgG (data not shown). The binding was competed by excess
amounts of unlabeled consensus ERE. When the mutants ERa  (N69K), ERa  (L296P), ERa
(K303R), ERa  (S309F), ERa  (E353V) and ERa  (M396V) were added, a shifted band of
similar intensity as the wild type was observed. The super-shifted band with the anti-ERa
antibody and competition with excess amounts of unlabeled consensus ERE were also similar
to those of the wild type. In contrast, the mutant ERa  (G160C) faintly bound to ERE, and the
intensity of the super-shifted band was weaker than that of the wild type. The mutant ERa
(411fsX7) was moderately bound to ERE.
   To investigate the cause of the faint bands with ERa  (G160C) and ERa  (411fsX7),
Western blot analyses of the in vitrotranslated ERa  proteins were performed. The in vitro
transcription/translation mixture that included the wild-type ERa  showed a distinct band with
66 kDa (Fig. 2B). The band corresponded to the full-length ERa  protein. No band was
observed with the in vitro transcription/translation mixture that included the empty pSG5
vector (mock). The in vitro transcription/translation mixtures that included the mutants except
ERa  (411fsX7) showed a band with the same mobility as that of the wild type. However, the
band density for ERa  (G160C) was prominently attenuated. The in vitro
transcription/translation mixture that included ERa  (411fsX7) showed a band with 46 kDa,
which corresponded to a truncated protein with 417 amino acids.
3.2. E2-dependent transactivation potency of mutated ER pro ins
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were performed. The responsiveness to E2 was assessed at concentrations ranging from 10
pM to 100 nM. In wild-type ERa , a significant increase in the transactivation was observed at
100 pM E2, with maximal transactivation (ca. 10-fold) at 100 nM E2. The concentration-
response curves of the mutant ERa  proteins except ERa  (E353V) and ERa  (411fsX7) were
similar to that of wild-type ERa . a  (E353V) and ERa  (411fsX7) did not show
transactivation at any concentration of E2. At 100 pM E2, the mutants ERa  (N69K), ERa
(L296P), ERa  (S309F), and ERa  (M396V) showed significant decreases of transactivation
compared with the wild-type ERa . With RT-PCR analyses, it was confirmed that the
expression levels of ERa  mRNA in the cells transfected with mutated ERa  expression
plasmids were almost the same as that of the wild type (data not shown).
3.3. Responsiveness to 4OHT and ICI 182,780 of mutated ER pro ins
  We investigated the responsiveness of the mutated ERa  pro ins to antiestrogens, 4OHT
and ICI 182,780. The cells transfected with the wild-type or mutated ERa  expression vector
were treated with 100 nM of 4OHT or ICI 182,780 in the presence of 10 nM E2. In the wild-
type ERa , the E2-dependent transactivation was markedly suppressed by 4OHT and ICI
182,780 (Fig. 4). The responsiveness of the mutants ERa  (N69K), ERa  (G160C), ERa
(L296P), ERa  (K303R) and ERa  (M396V) was almost the same as that of the wild-type ERa .
In contrast, the mutant ERa  (S309F) showed significantly (P < 0.05) lower antiestrogenicity
of 4OHT than did the wild-type ERa . The antiestrogenicity of 4OHT and ICI 182,780 was not
determined for the mutants ERa  (E353V) and ERa  (411fsX7), since these mutants were
inactive with E2.
  The antiestrogens 4OHT and ICI 182,780 sometimes act as an ER agonist [28]. To
examine the responsiveness of the mutated ERa  proteins to the estrogenicity of 4OHT and
ICI 182,780, the transcriptional activities were assessed in the absence of E2. In the wild-type
ERa , the transcriptional activity was about 2-fold increased by 4OHT. A similar activation by
4OHT was observed with the mutated ERa  (N69K), ERa  (G160C), ERa  (L296L), ERa
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(K303R), ERa  (S309F) and ERa  (M396V). However, the transactivation was not observed
with ERa  (E353V) and ERa  (411fsX7). Concerning ICI 182,780, no estrogenicity was
observed for the wild-type and mutated ERa  proteins.
4. Discussion
   We characterized the functional changes in human ERa  mutants with amino acid changes
of a single nucleotide substitution. In the present study, we investigated eight mutants in
which the amino acid changes of N69K and G160C are located in the AF-1 region; L296P,
K303R, and S309F are in the region responsible for AF-2a and nuclear localization; E353V,
M396A, and 411fsX7 are in the AF-2 region. Our findings provide evidence that some of
these mutations decrease the responsiveness to estrogens or antiestrogens.
   ERa  (G160C) did not obviously bind to ERE by gel-shift analyses, although the mutation
is not located in the C region. In contrast, with the luciferase assays, the mutant demonstrated
significant transactivation by E2, which was comparable with that of the wild-type ERa . A
likely explanation for these observations is that ERa  (G160C) protein could not be efficiently
translated under the in vitro transcription/translation system. Western blot analyses were able
to prove this (Fig. 2B). Andersen et al [16] considered that the amino acid substitution of
G160C might theoretically change the conformation of the receptor by creating disulfide
bridges with other cysteins in the protein. However, no dramatic change in the function of
ERa  (G160C) was observed in the present study. The ERa  (G160C) decreased the
responsiveness to E2 only at a low concentration.
   Although mutated ERa  (E353V) showed DNA-binding activity that was similar to that of
the wild-type ERa  (Fig. 2), no transactivation by E2 was observed at all (Fig. 3), indicating
that glutamic acid at 353 has a critical role in the E2-dependent transcriptional activity. This
observation is in accordance with a previous report of Brzozowski et al [29] who determined
the structure of the ligand-binding domain and E2 complex and suggested that glutamic acid
at 353 makes direct hydrogen bonds with E2. In addition, our study revealed that this mutant
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also did not respond to 4OHT.
   The G1231deletion causes a frame-shift at codon 411 which results in an early stop codon
at 418. Conceivably, an immature ERa  protein lacking over half of its ligand-binding domain
is produced. The production of the truncated ERa  (46 kDa) was confirmed by Western blot
analyses of the in vitro translated protein. Interestingly, the gel-shift assays showed a shifted
band with ERa  (411fsX7) with a similar mobility as that of the wild type, indicating that the
lack of the carboxy-terminal domain from codon 417 did not affect the DNA binding of ERa .
A change in the size or molecular weight in the truncated protein might not be detected with
the gel-shift assay. Although mutant ERa  (411fsX7) has the DNA binding potency, E2-
dependent transactivation was not observed because of the lack of E2 binding.
   Fuqua et al [30] reported that mutant ERa  (K303R) showed increased sensitivity to
estrogen as compared with that of the wild-type ERa  in stably transfected MCF-7 cells, which
showed increased proliferation at subphysiological levels of estrogen. In contrast, normal
responsiveness of the mutant to estrogens was observed with the luciferase assay in MDA-
MB-435 cells in the present study. With the luciferase assay, in MCF-7 cells both wild-type
and mutant ERa  (K303R) enhanced the E2-dependent transactivation (data not shown), but
the effects of the mutant were not higher than that of the wild-type ERa , indicating that the
discrepancy might not be due to differences in the cell lines. Considering the cell system, it
might be difficult to evaluate the ERa  r sponsiveness with the cell proliferation response,
because the change of the proliferation might result from the modulation of some factors
besides ERa  transactivation [31]. Fuqua et al [30] reported that mutant ERa  exhibited
estrogen binding affinity that was similar to that of wild-type ERa  bu  increased binding to
the coactivator transcriptional intermediary factor 2 (TIF2), which may partially explain its
increased estrogen responsiveness. It should be noted that the evaluation of the biological
effects of ERa  mutants might not be easy in MCF-7 cells, since endogenous ERa  is
simultaneously expressed. In the present study, we directly investigated the binding to DNA
and the transcriptional activity of mutant ERa , d found that ERa  (K303R) showed normal
responsiveness to estrogens and antiestrogens.
12
   4OHT and ICI 182,780 are known as a partial antagonist and a pure antagonist of ERa ,
respectively [32]. These compounds, especially 4OHT, sometimes work as agonists of ERa
[28]. The mechanisms of the antiestrogenic action of 4OHT and ICI 182,780 are different.
4OHT competes with E2 for ERa , whereas ICI 182,780 affects the stability and inhibits the
dimerization of ERa  [33,34]. In this study, the suppression of E2-induced transcriptional
activity by 4OHT and ICI 182,780 was observed in the wild-type ERa  and the mutant ERa
proteins except ERa  (E353V) and ERa  (411fsX7). Since there was no significant difference
in the antiestrogenicity of ICI 182,780 for the wild-type and mutated ERa , these mutations
may not be involved in the effects of ICI 182,780. In ERa  (S309F), although the percentage
of suppression by ICI 182,780 was similar to that of the wild type, the percentage of
suppression by 4OHT was significantly decreased compared to that of the wild-type ERa .
However, the transactivation potencies of ERa  (S309F) by E2 or 4OHT were almost equal to
those of the wild-type ERa . Previously, it was considered that the substitution of an
uncharged polar residue serine for a nonpolar residue phenylalanine may change the polarity
of the protein and alter its conformation [17]. Our results clarified that the amino acid change
of S309F may have an impact only on the antiestrogenicity of 4OHT. This mutant would
contribute to the resistance to antiestrogens in hormonal therapy.
   Previously, it was reported that some naturally occurring mutations, such as D351Y,
K303R, and Y537N, enhance the responsiveness to estrogens or antiestrogens. The D351Y
mutation increases the estrogenicity of 4OHT [35-37]. As discussed above, K303R showed
increased sensitivity to E2 [30]. In the absence of estrogens, the Y537N mutation exhibited a
higher transactivation level compared with the wild type [38]. Since hyper-responsiveness of
ER is one of the risk factors for breast cancer, the finding of these mutants in breast cancer
tissues is reasonable. In contrast, the mutations investigated in the present study did not reveal
hyper-responsiveness to estrogens. However, these mutants may modulate the responsiveness
to estrogen and antiestrogens.
   In summary, we found that some ERa  mutations decrease the responsiveness to estrogens
and antiestrogens. The functional analyses of the mutations as in this study will help to
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determine whether they indeed play a role in the progression of breast cancer or endometrial
cancer and/or resistance to hormonal therapy.
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Figure legends
Fig. 1. Schematic representation of the human ERa  cDNA. Exons are numbered in the
corresponding blocked region. The ATG start codon and the TAG stop codon are shown above.
ERa  protein is divided into structural and functional domains A-F. Region A/B is implicated
in the transactivating function (AF-1). Region C encodes the DNA-binding domain. Region D
contains a part of the ligand-dependent transactivation domain AF-2a and a portion of the
nuclear localization signal. Region E/F contains the ligand binding domain and the ligand-
dependent transactivation domain (AF-2). The locations of the mutations investigated in this
study are indicated with vertical arrows. Numbers indicate the nucleotide position on cDNA
when the A in the initiation codon is nucleotide 1. The amino acid changes are represented in
parentheses.
Fig. 2. A. Gel-shift assays of wild-type or mutated ERa  for binding to ERE. Wild-type or
mutated ERa  was translated in vitro. Radiolabeled oligonucleotide of cERE from the Xenopus
vitellogenin A2 gene was used as a probe. Cold oligonucleotides were used as a competitor at
50- and 200-fold molar excess. For super shift analysis, 2 µg of anti-ERa  antibodies were pre-
incubated with ERa  proteins on ice for 20 min. The lower arrow indicates the position of the
ERa  dependent band and the upper arrow indicates the super-shifted ERa  complex. B.
Western blot analyses of in vitro translated ERa  using mouse anti-human ERa  antibody. The
in vitro transcription/translation mixture expressing wild-type or mutated ERa except ERa
(G160C) and ERa  (411fsX7), showed a distinct band of 66 kDa. ERa  (411fsX7) showed a
distinct band of 46 kDa.
Fig. 3. E2 concentration-dependent transcriptional activities of wild-type or mutated ERa
protein in MDA-MB-435 cells. Wild-type or mutated ERa  expression plasmids were
transiently co-transfected with PGL3-3EREc38 and phRL-TK plasmids into the cells. After
24 hr, the cells were treated with various concentrations of E2 for 24 hr. The relative
19
luciferase activity was normalized with the Renilla luciferase activity and converted to fold
induction above the vehicle control value. Each column represents the mean ± SD of triplicate
determinations (* P < 0.05 and ** P < 0.001, compared with wild-type ERa ).
Fig. 4. Antiestrogenicities of 4OHT and ICI 182,780 for wild-type or mutated ERa pro eins in
MDA-MB-435 cells. Wild-type or mutated ERa  expression plasmids were transiently co-
transfected with PGL3-3EREc38 and phRL-TK plasmids into the cells. After 24 hr, the cells
were treated with 100 nM of 4OHT or 100 nM of ICI 182,780 in the presence of 10 nM of E2
for 24 hr. A. The relative luciferase activity was normalized to the R nilla luciferase activity.
B. Percentage of repression of the transcriptional activity by 4OHT or ICI 182,780. Each
column represents the mean ± SD of triplicate determinations (* P < 0.05, compared with the
wild-type ERa ). NS: no suppression.
Fig. 5. Estrogenicities of 4OHT and ICI 182,780 for wild-type or mutated ERa  protein in
MDA-MB-435 cells. Wild-type or mutated ERa  expression plasmids were transiently co-
transfected with PGL3-3EREc38 and phRL-TK plasmids into the cells. After 24 hr, the cells
were treated with 100 nM of 4OHT or 100 nM of ICI 182,780 for 24 hr. The relative
luciferase activity was normalized to the Renilla luciferase activity. Each column represents
the mean ± SD of triplicate determinations (* P < 0.05, compared with wild-type ERa ).
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Fig. 5. Komagata et al.
